Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial)
Post hoc analysis of data from the randomized ACUITY trial published in The American journal of cardiology (2014)
Abstract
Although lesion complexity is predictive of outcomes after balloon angioplasty, it is unclear whether complex lesions continue to portend a worse prognosis in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with contemporary interventional therapies. We sought to assess the impact of angiographic lesion complexity, defined by the modified American College of Cardiology/American Heart Association classification, on clinical outcomes after PCI in patients with ACS and to determine whether an interaction exists between lesion complexity and antithrombin regimen outcomes after PCI. Among the 3,661 patients who underwent PCI in the Acute Catheterization and Urgent Intervention Triage strategy study, patients with type C lesions (n = 1,654 [45%]) had higher 30-day rates of mortality (1.2% vs 0.6%, p = 0.049), myocardial infarction (9.2% vs 6.3%, p = 0.0006), and unplanned revascularization (4.3% vs 3.1%, p = 0.04) compared with those without type C lesions. In multivariate analysis, type C lesions were independently associated with myocardial infarction (odds ratio [95% confidence interval] = 1.37 [1.04 to 1.80], p = 0.02) and composite ischemia (odds ratio [95% confidence interval] = 1.49 [1.17 to 1.88], p = 0.001) at 30 days. Bivalirudin monotherapy compared with heparin plus a glycoprotein IIb/IIIa inhibitor reduced major bleeding complications with similar rates of composite ischemic events, regardless of the presence of type C lesions. There were no interactions between antithrombotic regimens and lesion complexity in terms of composite ischemia and major bleeding (p [interaction] = 0.91 and 0.80, respectively). In conclusion, patients with ACS with type C lesion characteristics undergoing PCI have an adverse short-term prognosis. Treatment with bivalirudin monotherapy reduces major hemorrhagic complications irrespective of lesion complexity with comparable suppression of adverse ischemic events as heparin plus glycoprotein IIb/IIIa inhibitor.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Among 3,661 ACS patients undergoing PCI, type C lesions (45%) were independently associated with higher 30-day myocardial infarction and composite ischemia rates; bivalirudin monotherapy reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor regardless of lesion complexity.
Why This Matters for Hirudotherapy
This analysis examined 3,661 ACS patients undergoing PCI in the Acute Catheterization and Urgent Intervention Triage strategy study to determine whether angiographic lesion complexity (type C vs. non-type C) affected 30-day outcomes and whether antithrombin regimen interacted with lesion complexity. Type C lesions were independently associated with myocardial infarction and composite ischemia at 30 days; bivalirudin monotherapy reduced major bleeding versus heparin plus GPIIb/IIIa inhibitor with comparable ischemic suppression, regardless of lesion complexity. The abstract makes no mention of hirudin, leeches, or any leech-derived substance, so no pharmacological or therapeutic link to
Citation
Reference (Vancouver style)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, et al. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). Am J Cardiol. 2014;114(11):1638-1645. doi:10.1016/j.amjcard.2014.09.003. PMID: 25312637
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026